Suven Life Sciences
SUVENNSE

Suven Life Sciences

₹327.6029.65 (9.95%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
305.00
Today’s high
336.00
52 week low
124.11
52 week high
305.50
Open price
305.00
Previous close
297.95
Live volume
1,06,64,300
Lower circuit
262.10
Upper circuit
393.10

Fundamentals

Market Cap
₹7,884Cr
ROE
-46.73%
P/E Ratio(TTM)
--
EPS(TTM)
-10.47
P/B Ratio
13.33
Dividend Yield
0.00%
Industry P/E
62.60
Book Value
22.40
Debt to Equity
0.03
Face Value
1

Financial performance

Quarterly
Yearly
All Financials
MAR '26
Revenue (Cr)
₹8.30
+48.75%
Profit (Cr)
-₹45.60
+55.26%
-150-100-50050
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Revenue growthValue
1Y (TTM)+209%
3Y CAGR+9%
Profit growthValue
1Y (TTM)-4%
3Y CAGR-9%

About

Suven Life Sciences is a biopharmaceutical company dedicated to discovering and developing novel pharmaceutical products for a wide range of Central Nervous System (CNS) disorders. The company's vision is to achieve a breakthrough innovation by singularly focusing on New Chemical Entities for CNS conditions, a commitment it has held for 20 years. It is uniquely positioned as the only Indian NCE-focused player with such a large basket of molecules specifically targeting disorders of the brain and spinal cord. Its core mission involves developing solutions for diseases with significant unmet medical needs, such as Alzheimer's, dementia, and narcolepsy, through its specialized research programs and clinical trials. Strategically, the company focuses on targets with novel and differentiated mechanisms of action, targeting indications that have high unmet needs and attractive commercial opportunities to ensure efficient development. This focused pursuit has resulted in a portfolio of 13 new chemical entities, which includes 7 assets in clinical stages and 6 projects in the research pipeline.;
CEO/MD
Shri Venkateswarlu Jasti
Founded in
1989
NSE symbol
SUVEN

Shareholding Pattern

Mar '26
Dec '25
Sep '25
Jul '25
Jun '25
Promoters
70.27%
Retail And Others
29.12%
Foreign Institutions
0.59%
Mutual Funds
0.01%
Other Domestic Institutions
0.01%

Mutual Funds Invested (1)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
₹317.60
+4.15 (1.32%)
L
    H
    3,511.5720.232.15
    Panacea BiotecPANACEABIO
    ₹551.20
    +2.95 (0.54%)
    L
      H
      3,352.56--4.02
      ₹121.10
      0.00 (--)
      L
        H
        547.98--13.68
        ₹2.96
        -0.08 (2.63%)
        L
          H
          23.03--2.75
          Livesquawk
          Suven Life Sciences reports successful Phase 1 results for SUVN-I6107. The company is advancing the SUVN-I6107 program to Phase 2 development.
          2026
          13
          May
          Quarterly & Annual Result
          Release date
          29
          Jan
          Quarterly Result
          Release date
          2025
          11
          Nov
          Quarterly Result
          Release date
          13
          Aug
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks